POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

Bastos-Oreiro, M ; de las Heras, A ; Presa, M ; Casado, MÁ ; Pardo, C ; Martín-Escudero, V ; Sureda, A

Value in health, 2022-01, Vol.25 (1), p.S44-S44 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível